Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

a™ involves the remodeling of the actin cytoskeleton (F-actin) of endothelial cells (cells that line the inside of blood vessels, including the retinal blood vessels) so that the adhesion molecules between these cells are tightly bound to the peripheral actin (cortical) resulting in tighter junctions among these cells, hence preventing vascular leakage from the blood compartment into tissue. The basic mechanism of action of Optina™ is described in a recently published manuscript entitled: "Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics" in Biochemical Biophysical Research Communications (BBRC 21 April 2012 http://dx.doi.org/10.1016/j.bbrc.2012.04.066). This is the first in a series of publications describing the biphasic effect of danazol on vascular permeability which is beneficial in reducing permeability (nano molar concentrations) and increasing permeability at the higher concentrations used in other approved indications (micro molar).

Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, noted, "A clinical study of Optina™ for DME conducted in a double masked, placebo controlled manner at Saint Michael Hospital in Toronto, Canada, confirmed the in vitro findings that the ultra-low dose of danazol is beneficial while the high dose is detrimental. Complete analysis of the Optina™ trial is underway by our CRO and results will be published in the proper venues following a pre-IND meeting with the FDA. Ampio is preparing for a pre-IND meeting with the FDA to discuss plans for a pivotal trial(s) in the US under the 505(b)2 registration."

About Diabetic Retinopathy, Diabetic Macular Edema and current treatments
Diabetic retinopathy is damage to the retina of the eyes caused by complications of diabetes mellitus and often resulting in loss of visual acuity and blindness.  Macular edema of th
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Md. , May 22, 2015  RegeneRx ... today announced a peer-reviewed publication of the results ... evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for the ... controlled adverse environment (CAE ® ) model.  The ... the results, which were previously disseminated by the ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... Inc. (Nasdaq: SLTM ), a global leader in ... 69, Chief Technology Officer and a member of the company,s ... 1, 2010. Mr. DeBenedictis will be available to advise the ... to remain active in the development of other emerging medical ...
... Md., Sept. 15 The U.S. Food and Drug ... Department of Justice (USDOJ), today announced that Forest Pharmaceuticals, ... company accepted responsibility for criminal actions including distribution of ... and obstruction of an FDA inspection. ...
Cached Medicine Technology:Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc. 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 3
(Date:5/22/2015)... Utah (PRWEB) May 22, 2015 Mountain Point ... host a ribbon cutting ceremony on Friday, May 29, 2015 ... p.m. to 6 p.m. The new medical center, set to ... North Triumph Boulevard, Lehi, UT 84043. , “The opening ... our team and the Utah County community,” said Kent Loosle, ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
(Date:5/22/2015)... Boston, Massachusetts (PRWEB) May 22, 2015 ... conditions is a difficult process. Historically providers have ... efforts by payers. Starting in 2015, Medicare has ... care coordination activities. Thanks to the launch of ... technology, providers and health systems using the platform ...
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
(Date:5/22/2015)... May 22, 2015 sweetFrog Enterprises, LLC. is ... Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store located ... was listed as #22 on the Inc. 500 list of ... lived and worked in East Texas for 20 years and ... owner of the Jacksonville, and nearby Palestine, sweetFrog locations. “We ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... Findings by UT Southwestern Medical Center researchers may suggest ... patients with blood cancers such as leukemia, lymphoma and myeloma. ... Cell , showed for the first time that adult blood ... that leads to transplant rejection. It also opens up further ...
... Kentucky on Aug. 3 announced that they were among the ... a lung transplant, using a device invented by two university ... "The device helps patients get oxygen into their blood ... dioxide and oxygenates the blood before returning it to the ...
... News) -- People with a rare condition where they are born ... study. The findings, published in the Aug. 4 online ... could shed light on how fingerprints are formed as well as ... the researchers pointed out. "We know that fingerprints are fully ...
... just one 4cl measure of spirits can increase the risk of ... appear to have the same effect, according to a study published ... Researchers from the Karolinska Institutet in Sweden followed 84,601 people ... in Vastmanland and Uppsala for a median of ten years. During ...
... (HealthDay News) -- The cost of dealing with health insurers ... than for Canadian physicians, a new study finds. The ... annually is $82,975 for U.S. physicians and $22,205 for physicians ... of the University of Toronto and colleagues. U.S. doctors ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. 3 ... detect prostate cancer and better evaluate a patient,s treatment options, ... their physician can use to help them decide whether it,s ... said lead researcher Dr. Scott Tomlins, a pathology resident at ...
Cached Medicine News:Health News:New use of artificial lung device pioneered at University of Kentucky 2Health News:Gene Mutation Can Leave People Without Fingerprints 2Health News:Drinking just 1 measure of spirits increases the risk of acute pancreatitis 2Health News:Urine Test Might Help Predict Prostate Cancer Risk 2Health News:Urine Test Might Help Predict Prostate Cancer Risk 3
With the sample processing core unit and intelligent process management, combines a wide variety of analytical modules to enable full consolidation of clinical chemistry and immunochemistry....
... The Roche Diagnostics Task Targeted ... state-of-the-art automation of pre- ... laboratories: decapping, sorting / archiving ... into bar code labeled secondary ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... precious time and gain efficiency in ... Automation System (LAS), the high-throughput aliquotting ... capabilities. The Olympus OLA2500 LAS is ... for medium- to high-volume laboratories. As ...
Medicine Products: